Results for tag: "Canertinib"

Canertinib is an oncology drug used to treat non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Canertinib is approved for the treatment of patients with locally advanced or metastatic NSCLC whose tumors have a specific genetic mutation known as EGFR exon 19 deletion or exon 21 L858R substitution mutations. It is also approved for the treatment of patients with metastatic NSCLC whose tumors have EGFR T790M mutation after prior treatment with an EGFR TKI. Canertinib is available in tablet form and is taken orally once daily. Common side effects include diarrhea, rash, and nausea. More serious side effects include liver damage, lung inflammation, and heart problems. The Canertinib market is a rapidly growing segment of the oncology drug market. It is a targeted therapy that is used to treat specific types of NSCLC, and is an important treatment option for patients with these types of cancer. Some companies in the Canertinib market include AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer. Show Less Read more